1. About 40% of all pituitary tumors are prolactinomas. 2. Most female patients have microadenomas. Prolactin may also be elevated in non-prolactinomatous pituitary tumors. 4. 90-95% of patients with prolactinomas do not have a progressive increase in tumor size, so controlling tumor size is not the goal of treatment. 5.The purpose of treatment for prolactin microadenoma is to reduce PRL level, restore normal gonadal function and solve infertility, while reducing and controlling tumor size in patients with macroadenoma is also the purpose of treatment. 6. The therapeutic effect of cabergoline is better than that of bromocriptine, including in terms of tolerance and convenience of taking the drug, reduction of prolactin secretion, restoration of gonadal function and reduction of tumor size. 7.Patients with elevated prolactin and no pituitary tumor detected by MRI should also take medication for treatment. 8. 1/3 of female patients with hyperprolactinemia are self-limiting, and pregnancy may also contribute to the normalization of prolactin secretion function, and it is possible that prolactin levels may return to normal after menopause in women with hyperprolactinemia.